Overview of Proheart

Quick Facts

Property	Description
Active Ingredient	Moxidectin
Form	Extended-release injectable suspension
Pharmacological Class	Macrocyclic Lactone (Milbemycin class)
General Purpose	Long-term parasite control
Origin	Semisynthetic derivative

Proheart is a specialized veterinary anthelmintic medication, available only via prescription, that utilizes the active ingredient Moxidectin to provide long-term, continuous protection against key parasites in dogs. It is classified as an endectocide, which is clinically recognized for its broad-spectrum effectiveness against both internal parasites, such as heartworm larvae, and external parasitic organisms.

The Core Identity: Moxidectin and its Classification

Proheart’s active compound is Moxidectin, which belongs to the Macrocyclic Lactone group, specifically the Milbemycin class. Moxidectin is a semisynthetic derivative, chemically derived from the natural fermentation product nemadectin. The unique mode of action involves selectively binding to glutamate-gated chloride ion channels in the nerve and muscle cells of susceptible parasites, thereby disrupting nerve signals and causing the organism to become paralyzed.

Composition and Delivery: The Sustained-Release Formulation

This product is distinctively administered as an extended-release injectable suspension, differentiating it from short-acting oral preventatives. The formulation consists of Moxidectin encased within sterile microspheres, which are suspended in an aqueous vehicle for subcutaneous injection. The design leverages Moxidectin’s high lipophilicity (fat solubility), allowing the medication to be sequestered in the dog's adipose tissue where it establishes a drug reservoir. This delivery system allows the long-acting nature of moxidectin to provide parasitic protection over extended periods.

General Purpose: The Main Benefit of Long-Term Parasite Control

The fundamental purpose of Proheart is to maintain long-term parasite control, ensuring continuous protection for an extended duration after a single administration. The mechanism provides consistent, protective drug levels in the bloodstream for many months, which is valuable in scenarios where consistent monthly dosing might be challenging. This ensures the effective elimination of the infective larvae of Dirofilaria immitis (heartworm) before they can mature, thereby preventing the development of heartworm disease and aiding in the control of certain hookworm infections.

What side effects are possible with Proheart?

Possible Side Effects and Safety Information

The official safety profile for Moxidectin extended-release injectable suspension is structured by the body systems affected and the frequency of reported events, as documented in regulatory reports. Adverse reactions are classified across several System-Organ Classes, including the Immune System, Gastrointestinal System, Neurological System, and Hepatic System.

Documented effects range from more common reports, such as vomiting, lethargy, diarrhea, and anorexia (decreased appetite), to serious and rare adverse events. The label explicitly identifies severe Serious Adverse Reactions (SARs), including anaphylactic/anaphylactoid reactions and Cardiovascular Shock, which in rare situations have resulted in death. Other serious events include documented cases of Immune-Mediated Hemolytic Anemia (IMHA) and Immune-Mediated Thrombocytopenia (ITP).

Time-Related Safety Patterns documented in regulatory information indicate that the majority of adverse reactions typically occur within the first 24 hours after injection, with severe allergic reactions often presenting within the first two hours.

Safety Restrictions and Considerations are explicitly defined. The medication is contraindicated in dogs with a history of hypersensitivity to the drug. Caution is necessary for dogs with pre-existing allergic disease, and it should not be administered to dogs that are sick, debilitated, underweight, or heartworm positive due to an increased risk of adverse reactions.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information on Proheart (Moxidectin) overdose manifestations and required emergency actions is strictly based on government regulatory labeling, such as the U.S. Food and Drug Administration (FDA) prescribing information.

Overdose or severe adverse reactions may involve several physiological systems and can escalate to life-threatening outcomes. No specific antidote is mentioned in the official labeling; management is limited to supportive care.

Classification	Documented Manifestations and Outcomes
Documented Manifestations	Vomiting (with or without blood), diarrhea, seizures, ataxia, trembling, lethargy, anorexia, fever, and hypersalivation. Allergic signs, including facial edema (swelling) and urticaria (hives), have also been reported.
Severe Outcomes	Life-threatening events may include anaphylaxis, cardiovascular shock, collapse, and in some cases, death. Liver disease (hepatopathy) and blood disorders (e.g., immune-mediated hemolytic anemia) have also been reported in association with severe events.
High-Risk Populations	Dogs with a pre-existing heartworm infection or those with clinically significant weight loss (>10%) are noted in labeling as being more likely to experience a severe reaction.

Immediate Actions and When to Seek Urgent Help

Owners must be advised to contact their veterinarian immediately if any signs of illness or toxicity are observed following administration. Severe reactions require emergency treatment by a veterinarian. In the event of accidental human ingestion, contact a Poison Control Center or a physician immediately, as directed by official human warnings. The required management for severe allergic reactions (anaphylaxis) is immediate symptomatic and supportive treatment, consistent with measures used for other injectable products.

Therapeutic Uses of Proheart

What Proheart Treats: Main Uses and Benefits

Proheart is commonly used for two core therapeutic domains: long-term prevention of Heartworm disease (Dirofilaria immitis) and managing and treating hookworm infections (Ancylostoma caninum and Uncinaria stenocephala).

The medication is relevant in contexts involving heightened systemic burden, addressing symptoms linked to organ-specific functional stress and intestinal discomfort. It helps with long-term prevention of Heartworm disease, which is a condition associated with severe physiological stress, while simultaneously assisting with maintaining functional stability during periods of active hookworm burden. The extended-release format supports the patient during difficult episodes by easing distress associated with the required preventative regimen. This consistency helps maintain a sense of stability when continuous coverage is a priority.

Quick Fact: Support for Parasitic Symptoms

Feature	Therapeutic Benefit
Primary Indication	Prevention of Heartworm disease
Secondary Action	Managing hookworm infections (treatment and control)
Symptom Axis	Symptoms linked to organ-specific functional stress
Clinical Scenario	Long-term maintenance of parasite-free status

Regulatory References

U.S. Food and Drug Administration

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Proheart?

Eligibility scope

Populations for whom use is allowed (as stated in label):

Healthy dogs six months of age and older (ProHeart 6 formulation) or twelve months of age and older (ProHeart 12 formulation).
Use is permitted in pregnant, lactating females, and breeding males, as safety studies showed no adverse effect on reproductive performance.

Populations for whom use is contraindicated:

Animals previously found to be hypersensitive to Moxidectin or to the ProHeart injectable formulation.

Age-related eligibility rules:

Minimum age of six months is required for the ProHeart 6 formulation, and twelve months for ProHeart 12. Effectiveness has not been evaluated in dogs below these minimum ages.

Condition-specific eligibility rules:

Must not be administered to dogs who are sick, debilitated, underweight, or who have a history of weight loss.
Use requires caution in dogs with pre-existing allergic disease (including food allergy, atopy, and flea allergy dermatitis).

Eligibility-related restrictions:

Dogs must be tested for heartworm infection; infected dogs are not eligible until they have been treated with an adulticide to remove adult heartworms.
Use requires caution when administered concurrently with vaccinations.

Resulting eligibility structure

Official eligibility statements:

Proheart is contraindicated in animals previously found to be hypersensitive to the drug or either formulation.
The medicine must not be administered to dogs who are sick, debilitated, underweight, or who have a history of weight loss.
Dogs must be six months of age or older (ProHeart 6) or twelve months of age or older (ProHeart 12) for approved use.
Dogs with an existing heartworm infection are not eligible until they have been successfully treated to remove adult heartworms.

Connection to the overall eligibility profile: The official regulatory documents define a restrictive eligibility profile based on minimum age, overall health status, and hypersensitivity. The label formally prohibits use in hypersensitive, sick, or underweight animals and restricts use based on age, ensuring the drug is limited to healthy, non-compromised patients that meet specific age and pre-existing parasite status requirements.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information regarding Proheart (moxidectin) interactions with other medicinal products focuses primarily on pharmacodynamic risks and population-specific considerations, as documented by authorities such as the U.S. Food and Drug Administration (FDA).

Documented Interaction Patterns

Category	Officially Documented Information
Medicinal Product Category	Vaccinations
Mechanistic Basis	Pharmacodynamic risk of Additive Hypersensitivity Reactions
Timing-Based Restriction	Mandatory Caution when administered concurrently

The regulatory profile mandates Caution when administering Proheart simultaneously with vaccinations. This restriction is documented due to reports of anaphylactic and anaphylactoid reactions following the co-administration of moxidectin microspheres and vaccines. This represents a formal constraint on simultaneous administration.

Population-Specific Caution

Administration also carries a Population-Specific Caution for dogs with pre-existing allergic disease, including conditions such as atopy, flea allergy dermatitis, and food allergy. This population is noted in regulatory documents as having a heightened risk for adverse reactions when the product is administered. No specific interactions involving metabolic enzymes (e.g., CYP) or drug transporters have been formally listed in the regulatory warnings for co-administered medicinal products.

Mechanism of Action

Molecular Mechanism: Selective Ion Channel Agonism

The core mechanism of Moxidectin involves acting as an agonist at glutamate-gated chloride ion channels (GluCl channels), specialized molecular targets found exclusively in the nerve and muscle cells of susceptible parasites. This highly selective binding forces the channel to open and remain open, leading to an uncontrolled, sustained influx of negatively charged chloride ions (Cl^-) into the cell.

Cascade: Hyperpolarization and Flaccid Paralysis

The excessive influx of chloride ions causes the parasite's nerve and muscle membranes to enter a state of irreversible hyperpolarization. This massive electrical disruption prevents the cells from generating the action potentials required for signal transmission, resulting in a neuromuscular blockade. The subsequent failure of efferent motor signals culminates in flaccid paralysis and the loss of movement.

Duration Mechanism: Sustained Reservoir Effect

The duration of the mechanism is maintained by its specific delivery system. After injection, Moxidectin is contained within microspheres that establish a drug reservoir within the host’s adipose tissue. This reservoir ensures the slow, continuous release of the compound into the circulation, maintaining consistent concentrations over many months to sustain the paralyzing effect on newly acquired larval stages.

Dosage and Administration Information

The administration of Proheart (Moxidectin extended-release injectable suspension) follows a precise protocol. The medicine is delivered via subcutaneous injection on an annual frequency, providing continuous protection for a 12-month period.

Administration Scope

The dose is 0.5 mg Moxidectin per kilogram of body weight, which corresponds to 0.05 mL of the constituted suspension per kilogram. The dosage is calculated based on the patient's weight at the time of treatment.

Preparation and Technique: Proheart is supplied as two components—microspheres and a sterile vehicle—which must be constituted (mixed) prior to use. This suspension must be allowed to stand for a minimum of 30 minutes after constitution and must be gently swirled before every use to maintain uniformity. The injection requires aseptic technique and is administered in the dorsum of the neck cranial to the scapula. No more than 3 mL should be given in a single injection site, necessitating site rotation for subsequent annual administrations.

Procedural Context

Proheart is indicated for use in patients 12 months of age and older. When initiating treatment for patients not previously on a preventative, or when switching from a monthly product, the injection is administered within one month of the last dose of the former medication or within one month of exposure to mosquitoes.

Connection to the overall use protocol: A structured, annual administration protocol for Proheart governs the dosage volume, delivery site, and preparation. This protocol involves precise weight-based dosing and specific steps for reconstitution and site rotation, which are necessary for the delivery and function of the extended-release subcutaneous formulation.

Recent Clinical Evidence

Proheart: Recent Clinical Evidence

Evidence for use in Long-Term Heartworm Disease Prevention

Research exploring outcomes in the context of heartworm prophylaxis involves controlled laboratory studies and large-scale randomized field trials. The main outcome monitored in pivotal studies was the heartworm status (absence or presence of adult heartworms). Field studies compared outcomes observed with the extended-release formula to those seen with comparator medications. Studies reported measurements of heartworm status tracked over the study period. This evidence contributes to understanding the long-term outcome patterns of the medication. However, uncertainty remains, as laboratory studies reported variability in outcomes against certain heartworm strains that demonstrated resistance, particularly late in the 12-month period.

Evidence for Hookworm Infection Treatment and Control

Research concerning outcomes in the context of existing hookworm infections (Ancylostoma caninum and Uncinaria stenocephala) is primarily derived from pivotal laboratory dose confirmation studies. Researchers monitored the quantification of adult and larval hookworm stages recovered from the dogs following administration. This research highlights changes measured in the existing hookworm population at the time of follow-up measurement, which is aligned with the required evidence for regulatory indication. The existing data provides limited published insight into whether the extended-release formula affects outcomes related to hookworm re-infection over the entire 12-month duration.

Long-Term Research and Research in Specific Patient Groups

The duration of outcomes has been a primary focus of research, with major field studies tracking outcomes over the full 12-month dosing interval. Observations were also recorded for up to 20 months post-administration. The principal patient population studied consisted of client-owned dogs that were 12 months of age and older. While evidence is well-characterized for the adult population, data for certain groups remain insufficient, as research examining specific comorbidity-defined groups is not broadly available in the regulatory-cited summaries.

Key Limitations and Areas of Research Uncertainty

Evidence for the hookworm claim is primarily derived from controlled laboratory settings, which may not fully reflect real-world patterns. Furthermore, laboratory studies exploring heartworm resistance strains have reported that findings were mixed against certain resistant parasites. Certainty remains low for outcomes against all potential resistant strains, and data for exploring long-term hookworm re-infection is still emerging.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Proheart (FAQ)

Q: Why do people use Proheart?

According to official product information, the medicine containing Moxidectin is indicated for the treatment of onchocerciasis, which is commonly known as river blindness. This condition is caused by the parasitic worm Onchocerca volvulus.

Q: What is the main ingredient or active substance in Proheart?

The primary active substance, as described in regulatory documents, is Moxidectin. The drug is classified as an anthelmintic, meaning it works against parasitic worms.

Q: Is Proheart a type of antibiotic?

No, Moxidectin is not an antibiotic. It is classified as an anthelmintic drug used to treat parasitic infections. Specifically, it belongs to a class of compounds known as macrocyclic lactones.

Q: Is Proheart the same type of medicine as other treatments for the same condition?

Official information describes Moxidectin as a second-generation macrocyclic lactone anthelmintic. Studies have examined its effect on the microfilarial load in comparison to other existing treatments used for the same condition, which is onchocerciasis.

Q: What kind of patient populations is Proheart generally intended for?

The medicine is indicated for use in both adults and pediatric patients who have onchocerciasis. To be eligible, patients must be aged 4 years and older and weigh at least 13 kg.

Q: Can Proheart be used in children or adolescents?

Yes, according to the official label, Moxidectin is indicated for use in pediatric patients. This includes children who are 4 years of age or older and weigh at least 13 kg.

Q: Are there different doses of Proheart, and what determines the dose?

The dosage is generally a single oral dose. The dosage for adults is a standard single oral dose. For pediatric patients, the dosage is determined by their body weight at the time of treatment.

Q: Are women who are pregnant or breastfeeding generally eligible for Proheart?

Regarding use during breastfeeding, official regulatory information states that it is not recommended during treatment with Moxidectin tablets. This caution extends for 7 days after the single dose has been taken.

Q: Does Proheart interact with common over-the-counter supplements?

Regulatory information indicates that there are no known significant drug interactions documented for the single-dose oral tablet. This applies to combinations with other prescribed medicines and is often assessed alongside the use of common over-the-counter products.

Q: If I already take multiple medicines, how does that affect the use of Proheart?

Official information on Moxidectin states there are no known significant interactions documented with the single-dose oral tablet. The overall medical history is the context in which the single dose is administered.

Q: Are there any known food items that might interact with Proheart?

The official instructions regarding administration indicate that the single oral dose can be taken with or without food. No specific food items are listed as interacting with the medicine.

Q: Can I take non-prescription pain relievers while using Proheart?

Regulatory information states that there are no known significant drug interactions documented for the single-dose oral tablet. This indicates that common non-prescription pain relievers are not listed as having documented significant interactions.

Q: What are the typical non-serious side effects associated with Proheart?

Common reported side effects include a general feeling of discomfort, joint or muscle pain, headache, itching skin, and flu-like symptoms. These reactions, along with vomiting and diarrhea, are often related to the body's response as the parasites are dying.

Q: Does Proheart have any known sedative effects?

The official label includes a warning about Symptomatic Orthostatic Hypotension. This condition may lead to symptoms such as dizziness or fainting.

Q: Are there reports of Proheart causing issues with sleep?

The medicine may cause general discomfort or flu-like symptoms, including unusual tiredness. While specific sleep disorders are not listed as adverse events, these overall physical feelings may indirectly affect rest.

Q: Is Proheart associated with any long-term cardiovascular concerns?

Reported adverse reactions include Symptomatic Orthostatic Hypotension (dizziness/fainting) and a fast, pounding, or irregular heartbeat as part of the body's reaction to the treatment. These are changes that typically resolve after treatment.

Q: How does Proheart affect the liver, based on regulatory information?

Official reports from clinical trials indicate that laboratory changes can occur, including increases in liver enzymes. Examples of these enzymes are alanine aminotransferase (ALT) and aspartate aminotransferase (AST).

Q: How is Proheart different from older medicines used for the same purpose?

Moxidectin is described in the medical literature as a second-generation macrocyclic lactone. Research has described findings where Moxidectin demonstrated a favorable reduction of microfilarial load in the skin compared to some other therapies for onchocerciasis.

Q: Is there a patient information leaflet (PIL) available online for Proheart?

Yes, regulatory requirements mandate that the full official label, including patient-friendly information, be available. This documentation is published and accessible via government databases such as the FDA's DailyMed.

Q: Is it common for people to experience no side effects at all while on Proheart?

Studies report that adverse events are often a result of the Mazzotti reaction. This is an expected allergic and inflammatory response that the body initiates as the microfilariae die, suggesting that some form of reaction is expected to occur.

How should Proheart be stored and disposed of?

How to Store and Dispose of ProHeart (Moxidectin)

The storage requirements for ProHeart are dictated by the product's two distinct forms: unconstituted and constituted.

Storage Conditions

Product Form	Required Temperature	Stability/Protection
Unconstituted Vials	Store between 15 and 25 C (59 to 77 F)	Protect from extended exposure to light.
Constituted Suspension	Store under refrigeration at 2 to 8 C (36 to 46 F)	ProHeart 6 is stable for 4 weeks; ProHeart 12 for 8 weeks.

Handling and Disposal

The product label explicitly states, “Keep this and all drugs out of the reach of children.” After mixing, the unused portion of the sterile vehicle and all needles must be properly discarded. The medication is designated as Not for human use, and contents must be disposed of in accordance with applicable regulations.

Proheart